Company Overview and News

7
Fujifilm wins appeal in battle with Xerox over aborted merger

2018-10-17 reuters
TOKYO (Reuters) - Japan’s Fujifilm Holdings Corp has won an appeal in its legal battles with Xerox Corp, with a New York court overturning preliminary injunctions requested by an activist investor that had blocked their planned merger.
4901 FUJIY FUJIF XRX IEP

24
50 Top Technology Dividend WallStars By Yield And Gains For October

2018-10-17 seekingalpha
WallStars all show positive broker target price upsides. Top WallStar Technology ten by net gains, STX, XRX, KLAC, CY, LRCX, RELL, CAMT, WDC, TIVO and XPER, averaged 61.15%, calculated 10/15/18.
LRCX CY XPER RELLB WDC STX KLAC XRX CAMT LYTS UMC NOK RELL TESS TIVO

 
Fujifilm wins appeal in battle with Xerox over scrapped merger

2018-10-17 channelnewsasia
TOKYO: Fujifilm Holdings Corp has won an appeal in its legal battle with Xerox Corp, with a US court overturning preliminary injunctions requested by activist investors that had blocked a planner merger.
4901 FUJIY FUJIF XRX

 
The Greater Cannabis Company Appoints Dr. Hock Tan as Chairman of Scientific Advisory Board

2018-10-04 globenewswire
Baltimore, MD, Oct. 04, 2018 (GLOBE NEWSWIRE) -- The Greater Cannabis Company, Inc. (OTCPK: GCAN) (“the Company”) a biotechnology company focused on innovative delivery systems for the Cannabis market, is pleased to announce that Dr. Hock Tan, Ph.D. will serve as Chairman of the Company’s Scientific Advisory Board. As chairman, Dr. Tan will help to advance ongoing research and development, formulation, manufacturing, as well as contributing to the Company’s intellectual property strategy.
GCAN XRX

107
Best And Worst-Performing Stocks In The S&P 500 Over The Last 20 Years And How They Have Performed In 2018

2018-09-27 seekingalpha - 2
It's hard to believe but only ten stocks that are part of the S&P 500 index posted negative returns over the last 20 years.
CPRT NWL GLSSP AMZN MS AKAM MO JBK BAC TFG CBS.WD XRX MAT CGBBW CPV WFCNP MNST IPG BAC GS CBS WFC C GSC CBS.A GSJ TSCO GJS

 
Why Is Xerox Stock Going Up?

2018-09-24 seekingalpha
Xerox stock has risen 20% in the current quarter, three times the S& P 500 performance.
XRX

15
Tech index refresh could give under-the-radar names their day in the sun

2018-09-24 channelnewsasia
A reshuffling of Wall Street benchmark industry sectors that transferred high-flying FANG stocks like Facebook Inc and Google-parent Alphabet Inc out of the technology label may be a boon to some under-the-radar companies that used to compete with them for investor attention.
STT FB TXN NFLX XRX V FII JNPR CSCO MSFT INTC AKAM CSCOI

15
Tech index refresh could give under-the-radar names their day in the sun

2018-09-24 reuters
NEW YORK (Reuters) - A reshuffling of Wall Street benchmark industry sectors that transferred high-flying FANG stocks like Facebook Inc (FB.O) and Google-parent Alphabet Inc (GOOGL.O) out of the technology label may be a boon to some under-the-radar companies that used to compete with them for investor attention.
STT FB TXN NFLX XRX V FII JNPR CSCO MSFT INTC AKAM CSCOI

29
50 Top Technology Dividend WallStars By Yield And Gains For September

2018-09-14 seekingalpha - 1
WallStars show positive broker target price upsides. Top WallStar Technology ten by broker estimated net gains, XRX, CY, DAKT, CAMT, RELL, LRCX, TIVO, LYTS, WDC, & XPER, averaged 52.39%, calculated.
LRCX CY XPER RELLB WDC STX XRX DAKT CAMT LYTS UMC NOK RELL QCOM TESS TIVO

63
Tracking Carl Icahn's Portfolio - Q2 2018 Update

2018-09-03 seekingalpha - 6
This article is part of a series that provides an ongoing analysis of the changes made to Carl Icahn’s 13F portfolio on a quarterly basis. It is based on Icahn’s regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Carl Icahn’s Portfolio series to get an idea of his investment philosophy and our previous update for the fund’s moves during Q1 2018.
VLTCP CQP CVI SDRPQ FCX TPCA VMW ENZN AFNL HRI NWL EGN VLTCW CI WBT VKSC ARII LNG GLPI SD XRX IEP NAV CNDT SDOCQ HLF UAN DVMT ERI CVRR VLTC MTW SDRXP HTZ SDRXQ

112
Tracking David Einhorn's Portfolio - Q2 2018 Update

2018-09-02 seekingalpha - 8
Greenlight's long/short ratio is at 96% long and 75% short compared to 111% long and 82% short last quarter.
TWX AZO MET BLMN DLTR TJX CEIX.WI SFM DSW CLPPZ AABA TWTR VNTR CLPR GLRE CNX.WI ADNT TWC XRX CNDT BHF ROKU GPS ATHN GRBK CCR MDCO NFLX PYPL HUN VOYA ESV ODP AAPL GM CEIX DDS XELA TPR TPX MU DG PRGO TSLA URBN FIVE CNX

 
Campbell Soup to sell international, fresh food units

2018-08-30 theedgemarkets
(Aug 30): Campbell Soup Co said on Thursday it would sell its international businesses and fresh refrigerated-foods unit, following a months-long strategic review and pressure from hedge fund investors to sell the whole company.
XRX

 
Campbell Soup to sell international, fresh food units

2018-08-30 channelnewsasia
Campbell Soup Co has decided to sell its international businesses and Fresh refrigerated-foods unit, the Wall Street Journal reported on Thursday, following a months-long strategic review and pressure from hedge fund investors to sell the whole company.
XRX

 
Campbell Soup to sell international and Fresh units: WSJ

2018-08-30 channelnewsasia
Campbell Soup Co has decided to sell its international businesses and Fresh refrigerated-foods unit, the Wall Street Journal reported on Thursday, following a months-long strategic review and pressure from hedge fund investors to sell the whole company.
XRX

12
Mizuho’s new leader Tatsufumi Sakai gears up to reform struggling mega-bank

2018-08-24 japantimes.co.jp
When Tatsufumi Sakai was named chief executive and president of Mizuho Financial Group this year, many bankers and investors were surprised.
MZHOF UL UNLYF ULVR UN SMFG UNLNF SMFNF XRX BABA 8316 8306 MUFG 8411 MBFJF MTU MFG

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to XRX / Xerox Corp. on message board site Silicon Investor.

Xerox (XRX) Xerox (XRX) Xerox (XRX) DELL VS XRX DELL VS XRX DELL VS XRX
CUSIP: 984121103